QuidelOrtho
QDEL
#4789
Rank
NZ$3.28 B
Marketcap
NZ$48.29
Share price
1.43%
Change (1 day)
-36.41%
Change (1 year)
Quidel is an American manufacturer of diagnostics testings that can be used to diagnose infectious diseases as well as cardiovascular and metabolic diseases.

P/E ratio for QuidelOrtho (QDEL)

P/E ratio as of February 2026 (TTM): -1.71

According to QuidelOrtho's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.70975. At the end of 2024 the company had a P/E ratio of -1.47.

P/E ratio history for QuidelOrtho from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-1.47-99.68%
2023-461-6863.93%
20226.81-15.25%
20218.04-13.99%
20209.34-77.84%
201942.270.96%
201824.7-113.08%
2017-188
2015-125-13.76%
2014-145-202.98%
201314012.81%
2012124

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Thermo Fisher Scientific
TMO
31.3-1,930.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Becton Dickinson
BDX
37.7-2,305.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Danaher
DHR
44.4-2,696.13%๐Ÿ‡บ๐Ÿ‡ธ USA
PerkinElmer
PKI
15.0-975.37%๐Ÿ‡บ๐Ÿ‡ธ USA
OraSure Technologies
OSUR
-3.39 98.13%๐Ÿ‡บ๐Ÿ‡ธ USA
Meridian Bioscience
VIVO
35.0-2,148.29%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.